DOCSLIB.ORG

Before We Begin, I Would Now Like to Ask Our Distinguished

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Before We Begin, I Would Now Like to Ask Our Distinguished 1 UNITED STATES OF AMERICA DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION + + + CENTER FOR DEVICES AND RADIOLOGICAL HEALTH MEDICAL DEVICES ADVISORY COMMITTEE + + + NEUROLOGICAL DEVICES PANEL + + + January 27, 2011 9:00 a.m. Hilton Washington DC North 620 Perry Parkway Gaithersburg, Maryland PANEL MEMBERS: THOMAS G. BROTT, M.D. Temporary Non-Voting Chair KAREN E. ANDERSON, M.D. Temporary Non-Voting Member KAREN B. DOMINO, M.D., M.P.H. Temporary Non-Voting Member KEVIN DUFF, Ph.D. Temporary Non-Voting Member JONAS H. ELLENBERG, Ph.D. Temporary Non-Voting Member DAVID C. GOOD, M.D. Temporary Non-Voting Member WAYNE K. GOODMAN, M.D. Temporary Non-Voting Member MAE O. GORDON, Ph.D. Temporary Non-Voting Member SCOTT Y.H. KIM, M.D. Temporary Non-Voting Member WILLIAM M. McDONALD, M.D. Temporary Non-Voting Member JANE S. PAULSEN, Ph.D. Temporary Non-Voting Member GUERRY M. PEAVY, Ph.D. Temporary Non-Voting Member CHRISTOPHER A. ROSS, M.D., Ph.D. Temporary Non-Voting Member GLENN T. STEBBINS, Ph.D. Temporary Non-Voting Member ANDREW WINOKUR, M.D., Ph.D. Temporary Non-Voting Member E. FRANCINE STOKES McELVEEN, J.D., M.S. Consumer Representative DAVID H. MUELLER, M.S. Industry Representative MICHELLE CARRAS Patient Representative OLGA I. CLAUDIO, Ph.D. Designated Federal Officer Free State Reporting, Inc. 1378 Cape Saint Claire Road Annapolis, MD 21409 (410) 974-0947 2 FDA REPRESENTATIVES: MALVINA B. EYDELMAN, M.D. Director, Division of Ophthalmic, Neurological and Ear, Nose and Throat Devices, Office of Device Evaluation GERETTA WOOD Director, Advisory Committee Program SANDY WALSH Press Contact FDA PRESENTERS: MARJORIE SHULMAN Program Operations Staff, Office of Device Evaluation LCDR BRADLEY CUNNINGHAM CDRH/ODE/DONED ANNA GEORGIOPOULOS, M.D. Medical Officer, FDA/CDRH/ODE/DONED PETER G. COMO, Ph.D. Neuropsychologist/Lead Reviewer, FDA/CDRH/ODE/DONED CARA KRULEWITCH, CNM, Ph.D., FACNM Branch Chief, OSB/DEPI/EERB2 ALLISON KOMIYAMA, Ph.D. Neurobiologist, FDA/CDRH/OSEL LAWRENCE PARK, A.M., M.D. Medical Officer, FDA/CDRH/ODE/DONED OPEN PUBLIC HEARING SPEAKERS: KENDRICK MOXON LORETTA WILSON SARAH H. LISANBY, M.D. PAMELA SULLIVAN, M.D. JAN EASTGATE VINCE BOEHM on behalf of LEONARD R. FRANK LAURA J. FOCHTMANN, M.D. BARBARA WINKLER RICHARD WEINER, M.D., Ph.D. ROBERT ROCA, M.D. WILLIAM NARROW, M.D., M.P.H. Free State Reporting, Inc. 1378 Cape Saint Claire Road Annapolis, MD 21409 (410) 974-0947 3 OPEN PUBLIC SPEAKERS: (cont.) JULIE K. HERSH JOHN BREEDING, Ph.D. ANITA HAGIN, RN, B.S.N. AMY LUTZ KENDRICK MOXON on behalf of EVELYN SCOGIN JAN EASTGATE on behalf of DIAN'NA POSTHAUER DOROTHY DUNDAS DANIEL FISHER, M.D., Ph.D. DANIEL FISHER, M.D., Ph.D., on behalf of CAROL JEAN REYNOLDS LAUREN TENNEY, M.Phil., M.A., M.P.A. DAVID BOGER, M.D. MARY ROSEDALE, Ph.D., PMHNP-BC, NEA-BC DONALD JOHNSON KATHERINE KITTY DUKAKIS Free State Reporting, Inc. 1378 Cape Saint Claire Road Annapolis, MD 21409 (410) 974-0947 4 INDEX PAGE CALL TO ORDER - Thomas G. Brott, M.D. 7 PANEL INTRODUCTIONS 7 CONFLICT OF INTEREST STATEMENT - Geretta Wood 9 APPOINTMENT OF TEMPORARY NON-VOTING MEMBERS- 12 Geretta Wood GENERAL ANNOUNCEMENTS - Geretta Wood 12 FDA PRESENTATION Device Classification and Reclassification - 13 Marjorie Shulman ECT History & Regulatory Background - 17 LCDR Bradley Cunningham QUESTIONS TO FDA 22 OPEN PUBLIC HEARING SPEAKERS Kendrick Moxon 25 Loretta Wilson 29 Sarah H. Lisanby, M.D. 32 Pamela Sullivan, M.D. 36 Jan Eastgate 39 Vince Boehm on behalf of Leonard R. Frank 42 Laura J. Fochtmann, M.D. 45 Barbara Winkler 48 Richard Weiner, M.D., Ph.D. 51 Robert Roca, M.D. 55 William Narrow, M.D., M.P.H. 58 Free State Reporting, Inc. 1378 Cape Saint Claire Road Annapolis, MD 21409 (410) 974-0947 5 INDEX PAGE OPEN PUBLIC HEARING SPEAKERS (cont.) Julie K. Hersh 64 John Breeding, Ph.D. 67 Anita Hagin, RN, B.S.N. 69 Amy Lutz 72 Kendrick Moxon on behalf of Evelyn Scogin 75 Jan Eastgate on behalf of Dian'na Posthauer 78 Dorothy Dundas 80 Daniel Fisher, M.D., Ph.D. 83 Daniel Fisher, M.D., Ph.D., on behalf of Carol Jean Reynolds 86 Lauren Tenney, M.Phil., M.A., M.P.A. 89 David Boger, M.D. 92 Mary Rosedale, Ph.D., PMHNP-BC, NEA-BC 95 Donald Johnson 98 QUESTIONS TO OPEN PUBLIC SPEAKERS 100 FDA PRESENTATION FDA Assessment of ECT - Anna Georgiopoulos, M.D. 137 Cognitive and Memory Adverse Events: 150 FDA Systematic Literature Review - Peter G. Como, Ph.D. FDA Safety Meta-Analyses: Cognition and Memory - 162 Cara Krulewitch, CNM, Ph.D., FACNM Neurological Changes and Death - Allison Komiyama, Ph.D. 165 FDA Effectiveness Review - Lawrence Park, A.M., M.D. 172 Free State Reporting, Inc. 1378 Cape Saint Claire Road Annapolis, MD 21409 (410) 974-0947 6 INDEX PAGE OPEN PUBLIC HEARING SPEAKER Katherine Kitty Dukakis 196 QUESTIONS TO FDA 198 ADJOURNMENT 238 Free State Reporting, Inc. 1378 Cape Saint Claire Road Annapolis, MD 21409 (410) 974-0947 7 M E E T I N G (9:00 a.m.) DR. BROTT: I would like to call this meeting of the Neurological Devices Panel to order. I'm Dr. Thomas G. Brott, the Chairperson of this Panel. I'm a neurologist who specializes in stroke and also Director of Research at Mayo Clinic in Florida. At this meeting, the Panel will discuss and make recommendations regarding the possible reclassification of devices indicated for use in electroconvulsive therapy. Before we begin, I would now like to ask our distinguished Panel members and FDA staff seated at this table to introduce themselves. Please state your name, your area of expertise, your position and affiliation, and why don't we start with Dr. Eydelman. DR. EYDELMAN: Good morning, and thank you everybody for making it here today. My name is Malvina Eydelman. I'm Director of the Division of Ophthalmic, Neurological and ENT Devices here at FDA. DR. GOODMAN: Good morning. I'm Wayne Goodman. I'm a psychiatrist, Chair of the Department of Psychiatry at Mount Sinai School of Medicine in New York, and my expertise is in psychopharmacology and use of devices. DR. KIM: Hi, I'm Scott Kim. I'm a psychiatrist and a bioethicist Free State Reporting, Inc. 1378 Cape Saint Claire Road Annapolis, MD 21409 (410) 974-0947 8 from the University of Michigan. DR. DUFF: My name is Kevin Duff. I'm a neuropsychologist in the Department of Neurology at the University of Utah, and I specialize in mild cognitive impairment and early dementia. DR. PAULSEN: Hi, my name is Jane Paulsen. I'm a neuropsychologist and Professor of Neurology and Psychiatry at the University of Iowa. MS. WOOD: I'm Geretta Wood. I'm the Director of the Advisory Committee staff for the Center for Devices and Radiological Health. The Designated Federal Officer, Dr. Olga Claudio, has been delayed in the weather this morning, so I will be filling in for her until her arrival. Thank you very much. DR. GOOD: Good morning. I'm Dr. David Good. I'm a neurologist, Professor and Chair of Neurology at Penn State University in Hershey, Pennsylvania. My major interest is stroke and rehabilitation, neurorehabilitation. DR. ROSS: Hi, I'm Chris Ross from Johns Hopkins. I'm a Professor of Psychiatry, also Professor of Neurology, Neuroscience, and Pharmacology. I do research in a variety of neurodegenerative diseases and also research in schizophrenia and affective disorder, and my clinical practice is mainly in geriatric psychiatry. DR. ELLENBERG: Good morning. I'm Jonas Ellenberg, Free State Reporting, Inc. 1378 Cape Saint Claire Road Annapolis, MD 21409 (410) 974-0947 9 Professor of Biostatistics and Associate Dean in the School of Medicine at the University of Pennsylvania. My interest is in mostly children's neurology, but I go with what's available. MS. CARRAS: Good morning. I'm Michelle Carras. I'm the Patient Representative. I'm a graduate student in public health from Johns Hopkins Bloomberg School of Public Health, and I have bipolar disorder and I have several generations of family members who have mood disorder. MS. STOKES McELVEEN: I'm Francine Stokes McElveen. I'm General Counsel, Coppin State University, a constituent institution of the University of Maryland Systems. MR. MUELLER: Good morning. My name is David Mueller. I'm the official Industry Representative. I have a consulting firm in medical device regulatory affairs and many years of experience in the field. DR. BROTT: Thank you. We may also have some individuals on the telephone. If you can hear me and introduce yourselves, please do so at this time. MS. WOOD: Okay. We will get a list of who is on the telephone and provide that to you later in the meeting. Good morning, everyone. We appreciate you making the effort to be here in the inclement weather, and we welcome you to this meeting of the Neurological Devices Panel. I will now read the Conflict of Interest Statement. Free State Reporting, Inc. 1378 Cape Saint Claire Road Annapolis, MD 21409 (410) 974-0947 10 The Food and Drug Administration is convening today's meeting of the Neurological Devices Panel of the Medical Devices Advisory Committee under the authority of the Federal Advisory Committee Act (FACA) of 1972. With the exception of the Industry Representative, all members and consultants of the Panel are special Government employees or regular Federal employees from other agencies and are subject to Federal conflict of interest laws and regulations. The following information on the status of this Panel's compliance with Federal ethics and conflict of interest laws are covered by, but not limited to, those found at 18 U.S.C.
Load more

Recommended publications
  • Suggestions to the Human Rights Committee for Disability-Related Questions to Consider for Its List of Issues for the United States
    Center for the Human Rights of Users and Survivors of Psychiatry1 Repeal Mental Health Laws Documenting and challenging forced psychiatric treatment Suggestions to the Human Rights Committee for disability-related questions to consider for its List of Issues for the United States The situation of people labeled with psychiatric disabilities in the United States raises questions under Articles 2, 6, 7, 9, 10, 16, 25 and 26 of the Covenant. We use the term “people labeled with psychiatric disabilities” to refer to those who identify as having experienced madness, mental health problems or trauma, or as having been labeled with a psychiatric diagnosis. These individuals are covered as persons with disabilities under the Americans with Disabilities Act2 and under the United Nations Convention on the Rights of Persons with Disabilities.3 “From Privileges to Rights: People Labeled with Psychiatric Disabilities Speak for Themselves” was the title of a significant report issued in January 2000 by the U.S. National Council on Disability.4 We consider the “medical model of mental health,” under which altered mental and emotional states are characterized as pathological medical conditions, to be incompatible with our human rights and dignity. The Committee on the Rights of Persons with Disabilities acknowledges that alternatives to the medical model of mental health, including peer support, need to be made available.5 This submission suggests questions to ask of the United States government, followed by a preliminary review of the current state of U.S. laws and practices. 1 For information on organizations submitting this report see Annex I. 2 42 USC chapter 126; see § 12102 Definition of disability.
    [Show full text]
  • United for a Revolution in Mental Health Care
    Winter 2009-10 www.MindFreedom.org Protesters give a Mad Pride injection to the psychiatric industry directly outside the doors of the American Psychiatric Association Annual Meeting during a “Festival of Resistance” co-sponsored by MindFreedom International and the California Network of Mental Health Clients. See page 8 for more. Victory! MindFreedom Helps Ray Sandford Stop His Forced Electroshock Mad Pride in Media Launched: Directory of Alternative Mental Health Judi Chamberlin Leads From Hospice United for a Revolution in Mental Health Care www.MindFreedom.org Published PbyAGE MFI • MindFreedom International Wins Campaigns for Human Rights and From the Executive Director: Everyone Has Something To Offer Alternatives in the Mental Health System Please join! BY DAVID W. OAKS all psychiatric oppression “BY This is a TUESDAY.” MindFreedom International Sponsor Group or Affiliate has a Because of generous support from place where www.MindFreedom.org (MFI) is one of the few groups liaison on the MFI Support Coalition MindFreedom groups and members, “So,” Judi said, “that’s what I MindFreedom in the mental health field that is Advisory Council. [email protected] in the last few months I have had want. By Tuesday.” members can post to forums independent with no funding from MFI’s mission: “In a spirit of the privilege of visiting MindFree- In that spirit, here are some tips for and blogs that are or links to governments, mental mutual cooperation, MindFreedom MindFreedom International dom International (MFI) activists in our members in effective leadership open to public health providers, drug companies, International leads a nonviolent 454 Willamette, Suite 216 Norway, Maine, Massachusetts, Min- in MindFreedom International, for a view.
    [Show full text]
  • Antipsychiatry Movement 29 Wikipedia Articles
    Antipsychiatry Movement 29 Wikipedia Articles PDF generated using the open source mwlib toolkit. See http://code.pediapress.com/ for more information. PDF generated at: Mon, 29 Aug 2011 00:23:04 UTC Contents Articles Anti-psychiatry 1 History of anti-psychiatry 11 Involuntary commitment 19 Involuntary treatment 30 Against Therapy 33 Dialectics of Liberation 34 Hearing Voices Movement 34 Icarus Project 45 Liberation by Oppression: A Comparative Study of Slavery and Psychiatry 47 MindFreedom International 47 Positive Disintegration 50 Radical Psychology Network 60 Rosenhan experiment 61 World Network of Users and Survivors of Psychiatry 65 Loren Mosher 68 R. D. Laing 71 Thomas Szasz 77 Madness and Civilization 86 Psychiatric consumer/survivor/ex-patient movement 88 Mad Pride 96 Ted Chabasinski 98 Lyn Duff 102 Clifford Whittingham Beers 105 Social hygiene movement 106 Elizabeth Packard 107 Judi Chamberlin 110 Kate Millett 115 Leonard Roy Frank 118 Linda Andre 119 References Article Sources and Contributors 121 Image Sources, Licenses and Contributors 123 Article Licenses License 124 Anti-psychiatry 1 Anti-psychiatry Anti-psychiatry is a configuration of groups and theoretical constructs that emerged in the 1960s, and questioned the fundamental assumptions and practices of psychiatry, such as its claim that it achieves universal, scientific objectivity. Its igniting influences were Michel Foucault, R.D. Laing, Thomas Szasz and, in Italy, Franco Basaglia. The term was first used by the psychiatrist David Cooper in 1967.[1] Two central contentions
    [Show full text]
  • HB-05298 Mendelsohn, Stephen
    Stephen Mendelsohn 171 Hartford Road, #19 New Britain, CT 06053-1532 [email protected] Testimony in support of HB 5298, An Act Concerning Involuntary Shock Therapy Senator Gerratana, Rep. Johnson, and members of the Public Health Committee: As a psychiatric survivor and member of Second Thoughts Connecticut, I strongly support HB 5298, An Act Concerning Involuntary Shock Therapy. This bill seeks to protect the right of people to say no to electroshock, a controversial and brain-disabling psychiatric intervention. While I have never had electroshock or insulin coma, being mislabeled "paranoid schizophrenic" and coerced into taking disabling neuroleptic drugs was horrible enough. HB 5298 is a modest bill. It does not ban electroshock, as the voters of Berkeley, CA did in a 1982 ballot referendum that passed with nearly 62% of the vote. The National Council on Disability, which Cathy Ludlum will cite in her testimony, has also taken a position against electroshock as a treatment modality (in addition to opposing forced treatment generally). According to an NCD report, "Public policy should move toward the elimination of electroconvulsive therapy and psychosurgery as unproven and inherently inhumane procedures." What we should strive for is fully informed, uncoerced consent. Unfortunately, institutional psychiatry is riddled with force, coercion, and deception, making truly informed consent difficult, if not nearly impossible. One cannot give informed consent to ECT if one is being threatened with involuntary commitment or forced drugging for refusing to sign the consent form. I would therefore urge you to consider strengthening this legislation by requiring "written informed, uncoerced consent" in section 17a-543 of the Connecticut General Statutes.
    [Show full text]
  • The Electroshock Quotationary®
    The Electroshock Quotationary® Leonard Roy Frank, Editor Publication date: June 2006 Copyright © 2006 by Leonard Roy Frank. All Rights Reserved. Dedicated to everyone committed to ending the use of electroshock everywhere and forever The Campaign for the Abolition of Electroshock in Texas (CAEST) was founded in Austin during the summer of 2005. The Electroshock Quotationary (ECTQ) was created to support the organization’s opposition to electroshock by informing the public, through CAEST’s website, about the nature of electroshock, its history, why and how it’s used, its effects on people, and the efforts to promote and stop its use. The editor plans to regularly update ECTQ with suitable materials when he finds them or when they are brought to his attention. In this regard he invites readers to submit original and/or published materials for consideration (e-mail address: [email protected]). CONTENTS Acknowledgements Introduction: The Essentials (7 pages) Text: Chronologically Arranged Quotations (146 pages) About the Editor ACKNOWLEDGEMENTS For their many kindnesses, contributions and suggestions to The Electroshock Quotationary, I am most grateful to Linda Andre, Ronald Bassman, Margo Bouer, John Breeding, Doug Cameron, Ted Chabasinski, Lee Coleman, Alan Davisson, Dorothy Washburn Dundas, Sherry Everett, John Friedberg, Janet Gotkin, Ben Hansen, Wade Hudson, Juli Lawrence, Peter Lehmann, Diann’a Loper, Rosalie Maggio, Jeffrey Moussaieff Masson, Carla McKague, Jim Moore, Bob Morgan, David Oaks, Una Parker, Marc Rufer, Sherri Schultz, Eileen Walkenstein, Ann Weinstock, Don Weitz, and Rich Winkel. INTRODUCTION: THE ESSENTIALS I. THE CONTROVERSY Electroshock (also known as shock therapy, electroconvulsive treatment, convulsive therapy, ECT, EST, and ECS) is a psychiatric procedure involving the induction of a grand mal seizure, or convulsion, by passing electricity through the brain.
    [Show full text]
  • Potential Conflicts of Interest Between Ect Researchers, Ect Device Manufacturers, Fda/Nimh
    POTENTIAL CONFLICTS OF INTEREST BETWEEN ECT RESEARCHERS, ECT DEVICE MANUFACTURERS, FDA/NIMH In 1985, NIMH used federal funds to pay for a “Consensus Conference on ECT”— organized by the American Psychiatric Association (APA), with the planning committee consisting of psychiatrists with long-standing financial relationships to the Electroconvulsive Therapy (ECT) device manufacturers. The two U.S. ECT device manufacturers are MECTA and Somatics, Inc. Between 1999 and 2009, NIMH provided more than $23.7 million of taxpayer money for grants for ECT research, including to those sitting on the APA ECT Task Forces.1 The FDA has relied, in part, upon APA ECT Task Force reports, which since 1978 have been prepared by committees whose members include psychiatrists with conflicts of interest with ECT device manufacturers. In 2010, DR. LAWRENCE PARK, FDA medical officer, co-wrote the FDA’s Executive Summary on ECT. He is a psychiatrist who has co-authored numerous studies on ECT.2 Before he joined the FDA, he served as the Director of Research and Attending Psychiatrist for the Somatic Therapies Unit at Massachusetts General Hospital, where ECT is administered.3 Its website states ECT does not cause brain damage and is a safe and relatively comfortable experience—contrary to thousands of ECT “consumers” who presented comments to the FDA stating the opposite.4 MECTA’s submission to the FDA in 2010 cited 18 studies by Harold Sackeim, Ph.D., 13 by Dr. Richard Weiner and 8 by Dr. Andrew Krystal—all of whom have conflicts of interest with MECTA and/or Somatics, Inc.5 Each has been a member of an APA ECT Task Force, with Dr.
    [Show full text]
  • An Analysis of Psychologist Postdoctoral Psychopharmacology
    Antioch University AURA - Antioch University Repository and Archive Student & Alumni Scholarship, including Dissertations & Theses Dissertations & Theses 2016 An Analysis of Psychologist Postdoctoral Psychopharmacology Training Materials for Critiques of Neurobiological Hypotheses of Depression's Etiology, Critical Analyses of the DSM's Rigor, and for Consumer/Survivor/Ex- Patient Content. Chris William Nicholas Rowe Antioch University Seattle Follow this and additional works at: http://aura.antioch.edu/etds Part of the Educational Assessment, Evaluation, and Research Commons, Other Pharmacy and Pharmaceutical Sciences Commons, and the Psychology Commons Recommended Citation Rowe, Chris William Nicholas, "An Analysis of Psychologist Postdoctoral Psychopharmacology Training Materials for Critiques of Neurobiological Hypotheses of Depression's Etiology, Critical Analyses of the DSM's Rigor, and for Consumer/Survivor/Ex-Patient Content." (2016). Dissertations & Theses. 305. http://aura.antioch.edu/etds/305 This Dissertation is brought to you for free and open access by the Student & Alumni Scholarship, including Dissertations & Theses at AURA - Antioch University Repository and Archive. It has been accepted for inclusion in Dissertations & Theses by an authorized administrator of AURA - Antioch University Repository and Archive. For more information, please contact [email protected], [email protected]. AN ANALYSIS OF PSYCHOLOGIST POSTDOCTORAL PSYCHOPHARMACOLOGY TRAINING MATERIALS FOR CRITIQUES OF NEUROBIOLOGICAL HYPOTHESES OF DEPRESSION’S
    [Show full text]
  • Electroshock Must Be Banned Now: Strategies of Resistance Don Weitz Psychout: a Conference for Organizing Resistance Against
    Electroshock Must Be Banned Now: Strategies of Resistance Don Weitz PsychOut: A Conference for Organizing Resistance Against Psychiatry, OISE, Toronto, 2010 Electroshock Must Be Banned… 2 If the body is the temple of the spirit, as I believe, the brain may be seen as the body’s inner sanctum, the holiest of places. To invade, violate, and injure the brain is a crime against the spirit, a desecration of the soul. - Leonard Roy Frank, electroshock survivor, activist, and author (1991) A part of me has been wiped away – ECT should be banned absolutely, no question. - Paivi Marshall, electroshock survivor (2005) ECT is brutal, unethical, torture…a crime against humanity…it must be stopped. - Sue Clark-Wittenberg, electroshock survivor (2005) Stopping shock treatment will require public outrage, organized resistance from survivor groups and psychiatric reformers, lawsuits, and state legislation. - Peter Breggin, M.D., psychiatrist (2007) As many of us are aware, electroshock (“ECT”) has never been officially banned or phased out anywhere in the world. I wish it were, and so do many other shock survivors, antipsychiatry activists, and human rights activists. I pay tribute to several shock survivors in Canada, the United States and Ireland who have courageously and publicly testified against shock and demanded its abolition: Sue Clark-Wittenberg, Wendy Funk, Carla McKague, Paivi Marshall, Linda Andre, Barbara Cody, Janet Gotkin, Wayne Lax, Mel Starkman, Leonard Frank, George Ebert, Ray Sandford, Mary Maddock - to name a few. Electroshock is not a medical treatment – it is an extremely serious violation of our human rights—and always causes harm, always causes brain damage (Frank, 1990; Breggin, 1998; Weitz, 2008).
    [Show full text]
  • The Atlantic Monthly | February 2001
    The Atlantic Monthly | February 2001 SHOCK AND DISBELIEF Electroconvulsive therapy was once psychiatry's most terrifying tool—blunt, painful, and widely abused. It is now a safe and effective treatment for a wide range of mental illnesses. But an unlikely trio of activist groups stands against it BY DANIEL SMITH n the cover of a pamphlet I was sent recently appears a photograph of an elderly man with bright bolts of electricity shooting outward from his temples. His teeth are clenched. His eyes are squeezed shut. His hair is standing on end. Holding the man's head secure is a leather strap that resembles the restraint on a prisoner in the electric chair. This is electroconvulsive therapy (ECT)—the psychiatric use of an electric current to stimulate a grand mal seizure—as seen through the eyes of the Citizens Commission on Human Rights, a lobbying group founded by the Church of Scientology and the most active and well-organized anti-ECT group in existence. It is a grim view, invoking coercion, barbarity, anguish—everything negative that has ever been associated with psychiatry. It is also the common view. Last fall I saw a patient receive ECT at McLean Hospital, a private psychiatric facility in Belmont, Massachusetts. There, in a well-lit treatment room, attended by a nurse, a psychiatrist, and an anesthesiologist, a middle-aged man suffering from hallucinations and depression lay unconscious on his back while two electrode paddles were placed on his head. A button was pressed, and the patient's right foot twitched lightly. Shortly afterward the patient awoke and was given a snack before being escorted back to his room.
    [Show full text]
  • Outside Mental Health Voices and Visions of Madness Books by Will Hall
    Outside Mental Health Voices and Visions of Madness Books by Will Hall Outside Mental Health: Voices and Visions of Madness Harm Reduction Guide to Coming Off Psychiatric Drugs (Available in 15 languages) Outside Mental Health Voices and Visions of Madness Will Hall Acclaim for Outside Mental Health: Voices and Visions of Madness “Will Hall’s Madness Radio has long been for many a refuge and an oasis from the overblown claims and corporate interests of American psychi- atry and Big Pharma. This collection of interviews and writings—bold, fearless, and compellingly readable—captures Madness Radio’s impor- tance and fierce independence, urging us to think differently and anew about the ‘thought disorders’ involved in illness and wellness, sanity and recovery. Required reading.” Christopher Lane author of Shyness: How Normal Behavior Became a Sickness “This is a brilliant book… Nicely written, and wonderfully grand and big- hearted in its exploration of the world of mental health and much more. Remarkable in scope, Outside Mental Health delves into autobiography, psychology, sociology, philosophy, and spirituality. Will Hall elevates the radio interview format into an art.” Robert Whitaker author of Anatomy of an Epidemic: Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness in America “Will Hall’s gentle wisdom shines through in this diverse collection of inti- mate interviews. Outside Mental Health adds to our collective understand- ing of the complexity of human suffering, and offers new opportunities for compassion
    [Show full text]
  • Food and Drug Administration Ombudsman Office Medical Devices Ombudsman CC
    1 MEMOMRANDUM TO: Food and Drug Administration Ombudsman Office Medical Devices Ombudsman CC: The Public and All Elected, Appointed, or Otherwise Employed Government Officials and Workers FROM: People who are Psychiatric Survivors, People who are Shock Treatment Survivors, Allies, and MindFreedom International Members CONTACT: Lauren Tenney, PhD, MPhil, MPA, Psychiatric Survivor (516) 319-4295/ (718) 273-8708 [email protected] SUBJECT: Official Public Complaint of FDA Processes Attempting to Down-Classify the Shock Device RE: Docket No. 2014-N–1210 for ‘‘Neurological Devices; Reclassification of Electroconvulsive Therapy Devices Intended for Use in Treating Severe Major Depressive Episode in Patients 18 Years of Age and Older Who Are Treatment-Resistant or Require a Rapid Response; Effective Date of Requirement for Premarket Approval for Electroconvulsive Therapy Devices for Certain Specified Intended Uses” and Docket No. FDA-2014-D-1318 for “Electroconvulsive Therapy (ECT) Devices for Class II Intended Uses: Draft Guidance for Industry, Clinicians and FDA Staff” This is a public official complaint concerning the processes the FDA is using in above referenced dockets. The dockets in question include one, proposing a rule to down- classify the shock device from a Class III device to a Class II device, which would place the shock device in the same category of devices such as eyeglasses or wheelchairs and two, draft guidance for the shock device as a Class II device. Please see this complaint underscored by the fact that in 2008 the Special Rapporteur on Torture and Other Cruel, Inhuman and Degrading Treatment of the United Nations Human Rights Council reported that electroshock may constitute torture or ill treatment (Interim Report to the General Assembly, July 28, 2008i).
    [Show full text]
  • Peter Lehmann
    Last update on July 24, 2012 About the Intrinsic Suicidal Effects of Neuroleptics Towards breaking the taboo and fighting therapeutical recklessness 1 Peter Lehmann Abstract Suicide is a frequent cause of death in people diagnosed with “schizophrenia.” These patients generally receive neuroleptics, which have an intrinsic suicidal effect. There are placebo studies, epidemiological surveys, first -hand reports, test subject experience and clinical research providing evidence about neuroleptic -caused depression and suicidality. Publications about the suicidal effects of neuroleptics — currently taboo—and suicide registers might reduce suicidality in “schizophrenics.” Current suicide registers run by former psy chiatric patients, by psychiatrists and by governmental administrations have been shown to have limited effectiveness, and meaningful programs to prevent suicide due to psychiatric treatment are needed. Publications about the suicidal effects of neurolepti cs — taboo until today —and effective suicide registers involving users and survivors of psychiatry would gather findings that could be used to warn the public, consumers, and caregivers. As long as there are so few alternatives beyond neuroleptic -based psych iatry, and as long as major pharmaceutical companies and professionals and organisations, sponsored by them, dominate the scientific and political discussion and suicide prevention programs and conceal the intrinsic suicidal effects in particular of neuroleptics, people have to protect themselves with advance directives and
    [Show full text]